速劲

Sujin Biopharma is a clinical-stage biotechnology company headquartered in Suzhou, China, focused on discovering and developing innovative small molecule drugs for cancer treatment. The company utilizes a proprietary structure-based drug design platform to target key drivers in the RAS/MAPK signaling pathway, which is frequently mutated in various cancers. Its lead candidate, SJ-007, is a potent and selective KRAS G12C inhibitor currently undergoing clinical evaluation for solid tumors, including non-small cell lung cancer. Additionally, the company is advancing a pipeline of inhibitors targeting SOS1 and other RAS-related proteins to address resistance mechanisms and improve patient outcomes. Sujin Biopharma aims to provide next-generation targeted therapies that overcome the limitations of current treatment options in oncology.